Drug Profile
Balstilimab - Agenus/Ludwig Institute for Cancer Research
Alternative Names: AGEN-2034; BAL - Agenus/Ludwig Institute for Cancer Research; RebmAb-700Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Agenus; Ludwig Institute for Cancer Research
- Developer Agenus; Oxford BioTherapeutics; Rottapharm Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer
- Phase II/III Solid tumours
- Phase II Adenocarcinoma; Colorectal cancer; Haemangiosarcoma; Lymphoma; Oropharyngeal cancer; Renal cell carcinoma; Soft tissue sarcoma
- Phase I/II Triple negative breast cancer
- Phase I Adenoid cystic carcinoma
Most Recent Events
- 03 Apr 2024 Centre Leon Berard in collaboration with Agenus plans a phase III CIME trial for Adenocarcinoma (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in France (IV) in May 2024 (NCT06346197)
- 01 Apr 2024 University of Southern California plans phase-Ib trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) in April 2024 (NCT06336902)
- 31 Mar 2024 Phase-II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease) in USA (IV) (NCT06300463)